UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.133

Sortiert nach

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

Nature reviews. Rheumatology, 2015-05, Vol.11 (5), p.276

2015

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory bone loss: pathogenesis and therapeutic intervention

Nature reviews. Drug discovery, 2012-03, Vol.11 (3), p.234-250

2012

Link zum Volltext

Verfügbarkeit prüfen

Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score

Annals of the rheumatic diseases, 2016-05, Vol.75 (5), p.811-818

2016

Link zum Volltext

Verfügbarkeit prüfen

Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets

Nature reviews. Rheumatology, 2019-11, Vol.15 (11), p.633-634

2019

Link zum Volltext

Verfügbarkeit prüfen

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor

The Journal of experimental medicine, 2016-09, Vol.213 (10), p.1937-1950

2016

Link zum Volltext

Verfügbarkeit prüfen

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

Arthritis research & therapy, 2014-02, Vol.16 (1), p.R56-R56

2014

Link zum Volltext

Verfügbarkeit prüfen

Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management

Annals of the rheumatic diseases, 2018-01, Vol.77 (1), p.18

2018

Link zum Volltext

Verfügbarkeit prüfen

New therapies for treatment of rheumatoid arthritis

The Lancet (British edition), 2007-12, Vol.370 (9602), p.1861-1874

2007

Link zum Volltext

Verfügbarkeit prüfen

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Annals of the rheumatic diseases, 2022-03, Vol.81 (3), p.335

2022

Link zum Volltext

Verfügbarkeit prüfen

Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions

Annals of the rheumatic diseases, 2012-10, Vol.71 (10), p.1702-1705

2012

Link zum Volltext

Verfügbarkeit prüfen

2018 update of the EULAR recommendations for the management of hand osteoarthritis

Annals of the rheumatic diseases, 2019-01, Vol.78 (1), p.16

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

Annals of the rheumatic diseases, 2014-03, Vol.73 (3), p.529-535

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Annals of the rheumatic diseases, 2017-06, Vol.76 (6), p.1101

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the rheumatic diseases, 2014-03, Vol.73 (3), p.516-528

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of biosimilars in oncology

The lancet oncology, 2016-11, Vol.17 (11), p.e502-e509

2016

Link zum Volltext

Verfügbarkeit prüfen

Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?

Annals of the rheumatic diseases, 2020-04, Vol.79 (4), p.445

2020

Link zum Volltext

Verfügbarkeit prüfen

Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review

Annals of the rheumatic diseases, 2014-01, Vol.73 (1), p.114-123

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the rheumatic diseases, 2017-06, Vol.76 (6), p.1113

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

The Lancet (British edition), 2008-03, Vol.371 (9617), p.987-997

2008

Link zum Volltext

Verfügbarkeit prüfen

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

The Lancet (British edition), 2016-12, Vol.388 (10061), p.2763-2774

2016

Link zum Volltext

Verfügbarkeit prüfen

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study

Arthritis research & therapy, 2023-06, Vol.25 (1), p.100-100, Article 100

2023

Link zum Volltext

Verfügbarkeit prüfen

Clocking in: chronobiology in rheumatoid arthritis

Nature reviews. Rheumatology, 2015-06, Vol.11 (6), p.349

2015

Link zum Volltext

Verfügbarkeit prüfen

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

The Lancet (British edition), 2014-01, Vol.383 (9914), p.321-332

2014

Link zum Volltext

Verfügbarkeit prüfen

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

The Lancet (British edition), 2013-03, Vol.381 (9870), p.918-929

2013

Link zum Volltext

Verfügbarkeit prüfen

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

Annals of the rheumatic diseases, 2012-05, Vol.71 (5), p.687-693

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(695)
Mit Volltextzugriff
(962)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Rheumatology
(826)
Science & Technology
(616)
Life Sciences & Biomedicine
(609)
Humans
(575)
Rheumatoid Arthritis
(310)
Internal Medicine
(287)
Female
(242)
Male
(233)
Arthritis, Rheumatoid - Drug Therapy
(212)
Middle Aged
(207)
Antirheumatic Agents - Therapeutic Use
(193)
Biological And Medical Sciences
(184)
Medical Sciences
(182)
Adult
(158)
Treatment Outcome
(152)
Immunology
(150)
Diseases Of The Osteoarticular System
(144)
Patients
(140)
Severity Of Illness Index
(140)
Aged
(114)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

Inflammatory bone loss: pathogenesis and therapeutic intervention

Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score

Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management

New therapies for treatment of rheumatoid arthritis

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions

2018 update of the EULAR recommendations for the management of hand osteoarthritis

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

Safety and efficacy of biosimilars in oncology

Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?

Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study

Clocking in: chronobiology in rheumatoid arthritis

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

Suchergebnisse filtern